<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="Therapeutics KandimallaRamesh12JohnAlbin3AbburiChandrika4VallamkonduJayalakshmi5http://orcid.org/0000-0002-9560-9948ReddyP. Hemachandrahemachandra.reddy@ttuhsc.edu6789[1], [2], [3], grid.416992.10000 0001 2179 3554Internal Medicine," exact="Texas Tech University" post="Health Sciences Center, [4], grid.170205.10000 0004 1936 7822University of"/>
 <result pre="Technology, [6], grid.416992.10000 0001 2179 3554Internal Medicine, Neuroscience &amp;amp; Pharmacology," exact="Texas Tech University" post="Health Sciences Center, [7], grid.416992.10000 0001 2179 3554Neurology, Departments"/>
 <result pre="Health Sciences Center, [7], grid.416992.10000 0001 2179 3554Neurology, Departments of" exact="School of Medicine," post="Texas Tech University Health Sciences Center, [8], grid.416992.10000 0001"/>
 <result pre="[7], grid.416992.10000 0001 2179 3554Neurology, Departments of School of Medicine," exact="Texas Tech University" post="Health Sciences Center, [8], grid.416992.10000 0001 2179 3554Public Health"/>
 <result pre="2179 3554Public Health Department of Graduate School of Biomedical Sciences," exact="Texas Tech University" post="Health Sciences Center, [9], grid.416992.10000 0001 2179 3554Department of"/>
 <result pre="3554Department of Speech, Language and Hearing Sciences, School Health Professions," exact="Texas Tech University" post="Health Sciences Center, epub: 2020-7-7111received: 2020-6-2accepted: 2020-7-8(C) , This"/>
 <result pre="source. These permissions are granted for the duration of the" exact="World Health Organization" post="(WHO) declaration of COVID-19 as a global pandemic. Abstract"/>
 <result pre="Abstract Keywords SARS-CoV-2 HCQ Remdesivir Protease inhibitor Vaccines Funding http://dx.doi.org/10.13039/100000016U.S." exact="Department of Health" post="and Human Services R01AG042178, R01AG47812, R01NS105473, and AG060767 Introduction"/>
 <result pre="coronavirus, severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) [1]. The" exact="World Health Organization" post="(WHO) named the respiratory disease as novel coronavirus disease"/>
 <result pre="transitions to two doses of 200 mg per day [21]." exact="Indian Council of Medical Research" post="scientists, in India, recommended asymptomatic health workers an HCQ"/>
 <result pre="in phase 2/3 stage NOVAVAX, iBio, Sichuan Clover Biopharmaceuticals, and" exact="University of Queensland" post="(GlaxoSmithKline) are focused on developing a recombinant vaccine based"/>
 <result pre="on developing a recombinant vaccine based on the spike protein." exact="University of Queensland" post="(GlaxoSmithKline) is using a molecular clamp stabilized spike protein."/>
 <result pre="to generate antigenicity. This vaccine is in its clinical trial." exact="Institut Pasteur" post="is planning to develop a vaccine against COVID-19 using"/>
 <result pre="are using adenovirus type 5 as a replication vector. The" exact="University of Hong Kong" post="is also developing a vaccine for COVID-19. It is"/>
 <result pre="(S protein), Generex/EpiVax (Ii-Key peptide), EpiVax/Univ. of Georgia (S protein)," exact="Sanofi" post="Pasteur (S protein by baculovirus), Heat Biologics/Univ. Of Miami"/>
 <result pre="protein by baculovirus), Heat Biologics/Univ. Of Miami (gp-96 backbone), and" exact="University of Saskatchewan" post="(adjuvanted microsphere peptide) are producing protein subunit-based vaccines. They"/>
 <result pre="LNP-encapsulated mRNA encoding RBD), China CDC/Tongji University/Stermina/Arcturus/Duke-NUS/BioNTech/Fosun Pharma/Pfizer (mRNA), and" exact="Imperial College London" post="(SaRNA) are developing RNA vaccines. These vaccines are in"/>
 <result pre="such as Immuno-Precise, MIGAL Galilee Research Institute, Doherty Institute, and" exact="Tulane University," post="did not mention the source for their vaccines. All"/>
</results>
